99% Savings - Buy Just @1 Rs X
Rpn 3 Tablet is a prescription medicine that is available as a Tablet. It is primarily used for the treatment of Schizophrenia. Rpn 3 Tablet also has some secondary and off-label uses. These are listed below.
The optimal dosage of Rpn 3 Tablet is largely dependent on the individual's body weight, medical history, gender and age. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. This information has been provided in detail in the dosage section.
Besides the aforementioned side effects, there are other adverse effects of Rpn 3 Tablet as well, which are listed below. Such side effects of Rpn 3 Tablet normally do not last long and go away once the treatment is completed. Consult your doctor if these side effects become worse or stay for a longer duration.
In addition, Rpn 3 Tablet's effect is Moderate during pregnancy and Severe for lactating mothers. Warnings related to Rpn 3 Tablet's effects on the liver, heart and kidney, if any, have been listed below.
Rpn 3 Tablet is contraindicated in people with pre-existing medical conditions like Tardive Dyskinesia, Kidney Disease, Liver Disease as it can result in adverse effects. Other conditions have been mentioned below in the Rpn 3 Tablet contraindications section.
Drug interactions for Rpn 3 Tablet have been reported in the medical literature. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Rpn 3 Tablet is considered not safe while driving, and is not addictive.
Rpn 3 Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Is the use of Rpn 3 Tablet safe for pregnant women?
Rpn may have some side effects during pregnancy. Pregnant women should discontinue the use of Rpn, and talk to their doctor, if they notice any discomfort.
Is the use of Rpn 3 Tablet safe during breastfeeding?
Rpn should not be taken without taking your doctor's advice, as it may have severe side effects on breastfeeding women.
What is the effect of Rpn 3 Tablet on the Kidneys?
Rpn rarely affects the kidneys.
What is the effect of Rpn 3 Tablet on the Liver?
Very few cases of side effects of Rpn on the liver have been reported.
What is the effect of Rpn 3 Tablet on the Heart?
Rpn may have mild side effects on the heart. Most people will never see any effect on the heart.
If you are suffering from any of the following diseases, you should not take Rpn 3 Tablet unless your doctor advises you to do so -
Is this Rpn 3 Tablet habit forming or addictive?
Forming a habit of Rpn 3 Tablet has not been reported.
Is it safe to drive or operate heavy machinery when consuming?
After taking Rpn 3 Tablet, you should not drive or work on any heavy machine, as Rpn 3 Tablet can make you drowsy.
Is it safe?
Yes, Rpn 3 Tablet is safe but you must consult your doctor before taking it.
Is it able to treat mental disorders?
Yes, taking Rpn 3 Tablet can treat mental disorders.
Interaction between Food and Rpn 3 Tablet
Rpn 3 Tablet may take longer to act if you eat some foods while taking it. Follow your doctor's advice on this.
Interaction between Alcohol and Rpn 3 Tablet
Consumption of alcohol and Rpn 3 Tablet together may have severe effects on your health.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Risperdal® (risperidone)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 441-442
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1101-1103